{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:02:44Z","timestamp":1794430964481,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HL170612"],"award-info":[{"award-number":["HL170612"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HL144002"],"award-info":[{"award-number":["HL144002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HL146153"],"award-info":[{"award-number":["HL146153"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HL154154"],"award-info":[{"award-number":["HL154154"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HL179818"],"award-info":[{"award-number":["HL179818"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24CDA1277521"],"award-info":[{"award-number":["24CDA1277521"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41587-025-02890-8","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:02:34Z","timestamp":1767607354000},"page":"1672-1683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2969-5876","authenticated-orcid":false,"given":"Shuo","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8570-3439","authenticated-orcid":false,"given":"Shiqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9906-9053","authenticated-orcid":false,"given":"Kaiyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5786","authenticated-orcid":false,"given":"Dashuai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-7059","authenticated-orcid":false,"given":"Ke","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2890_CR1","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2890_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2890_CR3","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315, 1600\u20131609 (2016).","journal-title":"JAMA"},{"key":"2890_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223\u2013249 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"2890_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/JCO.1983.1.2.126","volume":"1","author":"CM Balch","year":"2016","unstructured":"Balch, C. M. et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J. Clin. Oncol. 1, 126\u2013134 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2890_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin, E. et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J. Hepatol. 68, 1181\u20131190 (2018).","journal-title":"J. Hepatol."},{"key":"2890_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone, G. et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 19, 347\u2013355 (2018).","journal-title":"Lancet Oncol."},{"key":"2890_CR8","doi-asserted-by":"publisher","first-page":"e0246168","DOI":"10.1371\/journal.pone.0246168","volume":"16","author":"K Adam","year":"2021","unstructured":"Adam, K., Iuga, A., Tocheva, A. S. & Mor, A. A novel mouse model for checkpoint inhibitor-induced adverse events. PLoS ONE 16, e0246168 (2021).","journal-title":"PLoS ONE"},{"key":"2890_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","volume":"17","author":"CJ Langer","year":"2016","unstructured":"Langer, C. J. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497\u20131508 (2016).","journal-title":"Lancet Oncol."},{"key":"2890_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02390-y","volume":"24","author":"L Shui","year":"2025","unstructured":"Shui, L. et al. Bispecific antibodies: unleashing a new era in oncology treatment. Mol. Cancer 24, 212 (2025).","journal-title":"Mol. Cancer"},{"key":"2890_CR11","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1021\/acs.nanolett.5b05030","volume":"16","author":"C Wang","year":"2016","unstructured":"Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H. & Gu, Z. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Lett. 16, 2334\u20132340 (2016).","journal-title":"Nano Lett."},{"key":"2890_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/1535-7163.MCT-21-0234","volume":"21","author":"M Gilardi","year":"2022","unstructured":"Gilardi, M. et al. Microneedle-mediated intratumoral delivery of anti-CTLA-4 promotes cDC1-dependent eradication of oral squamous cell carcinoma with limited irAEs. Mol. Cancer Ther. 21, 616\u2013624 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2890_CR13","doi-asserted-by":"publisher","first-page":"115083","DOI":"10.1016\/j.addr.2023.115083","volume":"202","author":"AS Mikhail","year":"2023","unstructured":"Mikhail, A. S. et al. Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer. Adv. Drug Deliv. Rev. 202, 115083 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2890_CR14","doi-asserted-by":"publisher","first-page":"e2007557","DOI":"10.1002\/adma.202007557","volume":"33","author":"Q Jin","year":"2021","unstructured":"Jin, Q. et al. Nanoparticle-mediated delivery of inhaled immunotherapeutics for treating lung metastasis. Adv. Mater. 33, e2007557 (2021).","journal-title":"Adv. Mater."},{"key":"2890_CR15","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke, J. J., Bao, R., Sweis, R. F., Spranger, S. & Gajewski, T. F. WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers. Clin. Cancer Res. 25, 3074\u20133083 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2890_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 523, 231\u2013235 (2015).","journal-title":"Nature"},{"key":"2890_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s42003-020-0916-2","volume":"3","author":"J Waaler","year":"2020","unstructured":"Waaler, J. et al. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models. Commun. Biol. 3, 196 (2020).","journal-title":"Commun. Biol."},{"key":"2890_CR18","doi-asserted-by":"publisher","first-page":"109071","DOI":"10.1016\/j.celrep.2021.109071","volume":"35","author":"NC DeVito","year":"2021","unstructured":"DeVito, N. C. et al. Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Rep. 35, 109071 (2021).","journal-title":"Cell Rep."},{"key":"2890_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","volume":"125","author":"J Rodon","year":"2021","unstructured":"Rodon, J. et al. Phase 1 study of single-agent WNT974, a first-in-class porcupine inhibitor, in patients with advanced solid tumours. Br. J. Cancer 125, 28\u201337 (2021).","journal-title":"Br. J. Cancer"},{"key":"2890_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-020-05817-w","volume":"184","author":"JR Diamond","year":"2020","unstructured":"Diamond, J. R. et al. Phase Ib clinical trial of the anti-Frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res. Treat. 184, 53\u201362 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"2890_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrd4233","volume":"13","author":"M Kahn","year":"2014","unstructured":"Kahn, M. Can we safely target the WNT pathway. Nat. Rev. Drug Discov. 13, 513\u2013532 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2890_CR22","doi-asserted-by":"crossref","unstructured":"Battistoni, A. et al. Nasal administration of recombinant Neospora caninum secreting IL-15\/IL-15R\u03b1 inhibits metastatic melanoma development in lung. J. Immunother. Cancer 11, e006683 (2023).","DOI":"10.1136\/jitc-2023-006683"},{"key":"2890_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41551-022-00902-5","volume":"6","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng 6, 791\u2013805 (2022).","journal-title":"Nat. Biomed. Eng"},{"key":"2890_CR24","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1016\/j.matt.2022.06.012","volume":"5","author":"KD Popowski","year":"2022","unstructured":"Popowski, K. D. et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter 5, 2960\u20132974 (2022).","journal-title":"Matter"},{"key":"2890_CR25","doi-asserted-by":"crossref","unstructured":"Liu, M., Hu, S., Yan, N., Popowski, K. D. & Cheng, K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat. Nanotechnol. 19, 565\u2013575 (2024).","DOI":"10.1038\/s41565-023-01580-3"},{"key":"2890_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14344-7","volume":"11","author":"P-UC Dinh","year":"2020","unstructured":"Dinh, P.-U. C. et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat. Commun. 11, 1064 (2020).","journal-title":"Nat. Commun."},{"key":"2890_CR27","doi-asserted-by":"publisher","unstructured":"Zhang, S. W., Edwards, D. A., Langer, R. & Cheng, K. Inhalable materials and biologics for lung defence and drug delivery. Nat. Rev. Mater. https:\/\/doi.org\/10.1038\/s41578-025-00841-y (2025).","DOI":"10.1038\/s41578-025-00841-y"},{"key":"2890_CR28","doi-asserted-by":"crossref","unstructured":"Cheng, K. & Kalluri, R. Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. Extracell. Ves. 2, 100029 (2023).","DOI":"10.1016\/j.vesic.2023.100029"},{"key":"2890_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41551-019-0507-z","volume":"4","author":"AM Zickler","year":"2020","unstructured":"Zickler, A. M. & El Andaloussi, S. Functional extracellular vesicles aplenty. Nat. Biomed. Eng 4, 9\u201311 (2020).","journal-title":"Nat. Biomed. Eng"},{"key":"2890_CR30","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1039\/D0TB00744G","volume":"8","author":"S Rayamajhi","year":"2020","unstructured":"Rayamajhi, S. & Aryal, S. Surface functionalization strategies of extracellular vesicles. J. Mater. Chem. B 8, 4552\u20134569 (2020).","journal-title":"J. Mater. Chem. B"},{"key":"2890_CR31","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41551-021-00792-z","volume":"5","author":"D Gupta","year":"2021","unstructured":"Gupta, D. et al. Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles. Nat. Biomed. Eng 5, 1084\u20131098 (2021).","journal-title":"Nat. Biomed. Eng"},{"key":"2890_CR32","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ymthe.2021.01.020","volume":"29","author":"K Dooley","year":"2021","unstructured":"Dooley, K. et al. A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties. Mol. Ther. 29, 1729\u20131743 (2021).","journal-title":"Mol. Ther."},{"key":"2890_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cell.2019.02.029","volume":"177","author":"DK Jeppesen","year":"2019","unstructured":"Jeppesen, D. K. et al. Reassessment of exosome composition. Cell 177, 428\u2013445 (2019).","journal-title":"Cell"},{"key":"2890_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41556-021-00693-y","volume":"23","author":"FG Kugeratski","year":"2021","unstructured":"Kugeratski, F. G. et al. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat. Cell Biol. 23, 631\u2013641 (2021).","journal-title":"Nat. Cell Biol."},{"key":"2890_CR35","doi-asserted-by":"crossref","unstructured":"Simpson, R. J., Kalra, H. & Mathivanan, S. ExoCarta as a resource for exosomal research. J. Extracell. Vesicles 1, 18374 (2012).","DOI":"10.3402\/jev.v1i0.18374"},{"key":"2890_CR36","doi-asserted-by":"crossref","unstructured":"Lee, K. M., Seo, E. C., Lee, J. H., Kim, H. J. & Hwangbo, C. The multifunctional protein syntenin-1: regulator of exosome biogenesis, cellular function, and tumor progression. Int. J. Mol. Sci. 24, 9418 (2023).","DOI":"10.3390\/ijms24119418"},{"key":"2890_CR37","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb2530","volume":"14","author":"JH Hurley","year":"2012","unstructured":"Hurley, J. H. & Odorizzi, G. Get on the exosome bus with ALIX. Nat. Cell Biol. 14, 654\u2013655 (2012).","journal-title":"Nat. Cell Biol."},{"key":"2890_CR38","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/aps.2017.178","volume":"39","author":"SP Li","year":"2018","unstructured":"Li, S. P., Lin, Z. X., Jiang, X. Y. & Yu, X. Y. Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. Acta Pharmacol. Sin. 39, 542\u2013551 (2018).","journal-title":"Acta Pharmacol. Sin."},{"key":"2890_CR39","first-page":"267","volume":"3","author":"I Marquez-Rodas","year":"2015","unstructured":"Marquez-Rodas, I. et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann. Transl. Med. 3, 267 (2015).","journal-title":"Ann. Transl. Med."},{"key":"2890_CR40","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002\u20131014 (2021).","journal-title":"Lancet"},{"key":"2890_CR41","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","volume":"69","author":"H Harlin","year":"2009","unstructured":"Harlin, H. et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69, 3077\u20133085 (2009).","journal-title":"Cancer Res."},{"key":"2890_CR42","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","volume":"61","author":"R-R Ji","year":"2012","unstructured":"Ji, R.-R. et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1019\u20131031 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"2890_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"2890_CR44","doi-asserted-by":"publisher","first-page":"32289","DOI":"10.1074\/jbc.M111.247825","volume":"286","author":"Y Li","year":"2011","unstructured":"Li, Y. et al. N-Myc downstream-regulated gene 2, a novel estrogen-targeted gene, is involved in the regulation of Na+\/K+-ATPase. J. Biol. Chem. 286, 32289\u201332299 (2011).","journal-title":"J. Biol. Chem."},{"key":"2890_CR45","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.molimm.2006.08.006","volume":"44","author":"CH Khuu","year":"2007","unstructured":"Khuu, C. H., Barrozo, R. M., Hai, T. & Weinstein, S. L. Activating transcription factor 3 (ATF3) represses the expression of CCL4 in murine macrophages. Mol. Immunol. 44, 1598\u20131605 (2007).","journal-title":"Mol. Immunol."},{"key":"2890_CR46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311\u2013325 (2017).","journal-title":"Cancer Cell"},{"key":"2890_CR47","doi-asserted-by":"publisher","first-page":"e714","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing BATF3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, e714 (2017).","journal-title":"Cancer Cell"},{"key":"2890_CR48","doi-asserted-by":"crossref","unstructured":"Reschke, R. et al. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J. Immunother. Cancer 9, e003521 (2021).","DOI":"10.1136\/jitc-2021-003521"},{"key":"2890_CR49","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1189\/jlb.71.4.669","volume":"71","author":"E Padovan","year":"2002","unstructured":"Padovan, E., Spagnoli, G. C., Ferrantini, M. & Heberer, M. IFN-\u03b12a induces IP-10\/CXCL10 and MIG\/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J. Leukoc. Biol. 71, 669\u2013676 (2002).","journal-title":"J. Leukoc. Biol."},{"key":"2890_CR50","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382\u2013386 (2018).","journal-title":"Nature"},{"key":"2890_CR51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio, M. et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell 177, 414\u2013427 (2019).","journal-title":"Cell"},{"key":"2890_CR52","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang, Y. et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 28, 862\u2013864 (2018).","journal-title":"Cell Res."},{"key":"2890_CR53","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1126\/science.1222879","volume":"337","author":"CY Janda","year":"2012","unstructured":"Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C. & Garcia, K. C. Structural basis of Wnt recognition by Frizzled. Science 337, 59\u201364 (2012).","journal-title":"Science"},{"key":"2890_CR54","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917\u2013927 (2012).","journal-title":"Cancer Res."},{"key":"2890_CR55","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","volume":"72","author":"W Peng","year":"2012","unstructured":"Peng, W. et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible chemokines. Cancer Res. 72, 5209\u20135218 (2012).","journal-title":"Cancer Res."},{"key":"2890_CR56","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells. J. Exp. Med. 208, 2005\u20132016 (2011).","journal-title":"J. Exp. Med."},{"key":"2890_CR57","doi-asserted-by":"publisher","first-page":"1663043","DOI":"10.1080\/20013078.2019.1663043","volume":"8","author":"G Corso","year":"2019","unstructured":"Corso, G. et al. Systematic characterization of extracellular vesicle sorting domains and quantification at the single molecule\u2013single vesicle level by fluorescence correlation spectroscopy and single particle imaging. J. Extracell. Vesicles 8, 1663043 (2019).","journal-title":"J. Extracell. Vesicles"},{"key":"2890_CR58","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/2159-8290.CD-21-0190","volume":"11","author":"MJ Parsons","year":"2021","unstructured":"Parsons, M. J., Tammela, T. & Dow, L. E. WNT as a driver and dependency in cancer. Cancer Discov. 11, 2413\u20132429 (2021).","journal-title":"Cancer Discov."},{"key":"2890_CR59","doi-asserted-by":"crossref","unstructured":"Gajos-Michniewicz, A. & Czyz, M. WNT signaling in melanoma. Int. J. Mol. Sci. 21, 4852 (2020).","DOI":"10.3390\/ijms21144852"},{"key":"2890_CR60","doi-asserted-by":"publisher","first-page":"e104509","DOI":"10.15252\/embj.2020104509","volume":"40","author":"S Li","year":"2021","unstructured":"Li, S. et al. PIF1 helicase promotes break-induced replication in mammalian cells. EMBO J. 40, e104509 (2021).","journal-title":"EMBO J."},{"key":"2890_CR61","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Thery","year":"2018","unstructured":"Thery, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750 (2018).","journal-title":"J. Extracell. Vesicles"},{"key":"2890_CR62","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1182\/blood-2010-02-271841","volume":"116","author":"SP McDermott","year":"2010","unstructured":"McDermott, S. P., Eppert, K., Lechman, E. R., Doedens, M. & Dick, J. E. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 116, 193\u2013200 (2010).","journal-title":"Blood"},{"key":"2890_CR63","doi-asserted-by":"publisher","first-page":"102770","DOI":"10.1016\/j.jbc.2022.102770","volume":"299","author":"S Liu","year":"2023","unstructured":"Liu, S. et al. DNA repair protein RAD52 is required for protecting G-quadruplexes in mammalian cells. J. Biol. Chem. 299, 102770 (2023).","journal-title":"J. Biol. Chem."},{"key":"2890_CR64","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41418-018-0078-7","volume":"25","author":"S Zhenilo","year":"2018","unstructured":"Zhenilo, S. et al. DeSUMOylation switches Kaiso from activator to repressor upon hyperosmotic stress. Cell Death Differ. 25, 1938\u20131951 (2018).","journal-title":"Cell Death Differ."},{"key":"2890_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03004-9","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu, S. et al. FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction. Cell Death Dis. 11, 804 (2020).","journal-title":"Cell Death Dis."},{"key":"2890_CR66","unstructured":"Hugo W. et al. mRNA expressions in pre-treatment melanomas undergoing anti-PD-1 checkpoint inhibition therapy. Gene Expression Omnibus https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE78220 (2016)."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-025-02890-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-025-02890-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-025-02890-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:03:05Z","timestamp":1791756185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-025-02890-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2890"],"URL":"https:\/\/doi.org\/10.1038\/s41587-025-02890-8","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"10 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}